(Q33753705)

29 July 2017

1 reference

14 September 2020

1 reference

systematic review

1 reference

title

Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

29 July 2017

1 reference

14 September 2020

1 reference

19 September 2019

1 reference

1 reference

14 September 2020

1 reference

1 reference

1 reference

5

Leonard Leibovici

1 reference

29 July 2017

4

Anat Gafter-Gvili

1 reference

29 July 2017

2

Irit Ben-Aharon

1 reference

29 July 2017

6

Salomon M Stemmer

1 reference

29 July 2017

Luisa Bonilla

1

1 reference

29 July 2017

Liat Vidal

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

23 November 2010

1 reference

Journal of the National Cancer Institute

29 July 2017

15 December 2010

5 references

13 March 2019

3 April 2019

17 June 2019

19 September 2019

14 September 2020

6 references

29 July 2017

13 March 2019

3 April 2019

17 June 2019

19 September 2019

14 September 2020

102

1 reference

29 July 2017

issue

24

1 reference

29 July 2017

page(s)

1845-1854

1 reference

Creative Commons Attribution-NonCommercial

29 July 2017

copyright license

5 references

13 March 2019

3 April 2019

17 June 2019

19 September 2019

14 September 2020

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Dose-dense chemotherapy for primary breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Statistical aspects of the analysis of data from retrospective studies of disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAK

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Bias in meta-analysis detected by a simple, graphical test

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Operating characteristics of a rank correlation test for publication bias

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Average relative dose intensity and the impact on design of clinical trials.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Meta-analysis in clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

A Gompertzian model of human breast cancer growth.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ409

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ409

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3001963

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

30 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ409

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21098761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21098761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21098761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JNCI/DJQ409

1 reference

29 July 2017

1 reference

29 July 2017

1 reference